艾沙康唑在儿童毛霉病治疗中的研究进展与临床思考

doi:10.12372/jcp.2026.25e0937

临床儿科杂志 ›› 2026, Vol. 44 ›› Issue (6): 589-594.doi: 10.12372/jcp.2026.25e0937

• 文献综述 • 上一篇

艾沙康唑在儿童毛霉病治疗中的研究进展与临床思考

施杰娜¹^,², 张俊琦³, 沈珑慧²()

¹ 浙江中医药大学（浙江杭州 310053）
² 宁波大学附属妇女儿童医院（浙江宁波 315012）
³ 复旦大学附属儿科医院（上海 201102）

收稿日期:2025-08-01 修回日期:2025-10-21 录用日期:2025-11-20 出版日期:2026-06-15 发布日期:2026-06-04
通讯作者: 沈珑慧 E-mail:nbslh22@163.com
作者简介:第一联系人：作者贡献（Authors’ Contributions）
施杰娜负责相关文献查询以及文章撰写，张俊琦参与思路指导以及文献查询，沈珑慧给予总体指导。
基金资助:
宁波市医学重点学科(2026-A34);吴阶平医学基金会临床科研专项资助基金(320.6750.2023-25-3)

Research progress and clinical implications of isavuconazole in the treatment of pediatric mucormycosis

SHI Jiena¹^,², ZHANG Junqi³, SHEN Longhui²()

¹ Zhejiang Chinese Medical University, Hangzhou 310053, Zhejiang, China
² The Affiliated Women and Children's Hospital of Ningbo University, Ningbo 315012, Zhejiang, China
³ Children’s Hospital of Fudan University, Shanghai 201102, China

Received:2025-08-01 Revised:2025-10-21 Accepted:2025-11-20 Published:2026-06-15 Online:2026-06-04
Contact: SHEN Longhui E-mail:nbslh22@163.com

摘要/Abstract

摘要：

毛霉病是毛霉目真菌引起的感染性疾病。其病死率高、有效抗感染药物选择有限，导致儿童毛霉病的诊治颇具挑战性。艾沙康唑作为一种新型三唑类抗真菌药，是毛霉病治疗的新选择。尽管艾沙康唑目前已在我国获批上市，但是其在儿童毛霉病中的应用数据极为有限。本文综述了艾沙康唑治疗儿童毛霉病的研究进展，介绍了艾沙康唑的作用机制、药代动力学、与其他抗真菌药的对比，论证了艾沙康唑在儿童毛霉病治疗中潜在的有效性与安全性，讨论了其对于儿童的用法用量及治疗药物监测的必要性，从而为儿童毛霉病的治疗药物使用提供参考。

关键词: 艾沙康唑, 毛霉病, 儿童

Abstract:

Mucormycosis is an infectious disease caused by fungi in the order Mucorales. Due to its high mortality rate and limited treatment options, treating mucormycosis in children remains challenging. Isavuconazole, a novel triazole antifungal agent, has offered a new option for treating mucormycosis. Though isavuconazole has been approved for marketing in China, data on its use in pediatric mucormycosis remain extremely limited. This article reviews the research progress of isavuconazole in treating pediatric mucormycosis, introduces its mechanism of action, pharmacokinetics, and comparison with other antifungal drugs. It also analyzes the potential efficacy and safety of isavuconazole in treating pediatric mucormycosis, and discusses its dosage and administration in children and the necessity of therapeutic drug monitoring, thus providing references for the clinical use of therapeutic drugs in pediatric mucormycosis.

Key words: isavuconazole, mucormycosis, child

中图分类号:

施杰娜, 张俊琦, 沈珑慧. 艾沙康唑在儿童毛霉病治疗中的研究进展与临床思考[J]. 临床儿科杂志, 2026, 44(6): 589-594.

SHI Jiena, ZHANG Junqi, SHEN Longhui. Research progress and clinical implications of isavuconazole in the treatment of pediatric mucormycosis[J]. Journal of Clinical Pediatrics, 2026, 44(6): 589-594.

图/表 2

参考文献 21

[1]	中国医药教育协会真菌病专业委员会, 中国毛霉病专家共识工作组. 中国毛霉病临床诊疗专家共识(2022)[J]. 中华内科杂志, 2023, 62(6) : 597-605.
	Medical Mycology Society of Chinese Medicine and Education Association, Chinese Mucormycosis Expert Consensus Group. Expert consensus on diagnosis and management of mucormycosis in China (2022)[J]. Zhonghua Neike Zazhi, 2023, 62(6): 597-605.
[2]	Cornely OA, Alastruey-Izquierdo A, Arenz D, et al. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European confederation of medical mycology in cooperation with the mycoses study group education and research consortium[J]. Lancet Infect Dis, 2019, 19(12): e405-e421.
[3]	中华医学会血液学分会抗感染学组. 艾沙康唑临床应用专家共识(2023版)[J]. 临床血液学杂志, 2023, 36(5): 295-302.
	Anti Infection Group, Chinese Society of Hematology, Chinese Medical Association. Consensus recommendations for the clinical application of isavuconazole (2023)[J]. Linchuang Xueyexue Zazhi, 2023, 36(5): 295-302.
[4]	Badali H, Cañete-Gibas C, McCarthy D, et al. Epidemiology and antifungal susceptibilities of mucoralean fungi in clinical samples from the United States[J]. J Clin Microbiol, 2021, 59(9): e0123021.
[5]	Marty FM, Ostrosky-Zeichner L, Cornely OA, et al. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis[J]. Lancet Infect Dis, 2016, 16(7): 828-837.
[6]	Schwartz S, Cornely OA, Hamed K, et al. Isavuconazole for the treatment of patients with invasive fungal diseases involving the central nervous system[J]. Med Mycol, 2020, 58(4): 417-424.
[7]	Qin J, Bi H, Tang G, et al. Real-world effectiveness and safety of isavuconazole versus amphotericin B for patients with invasive mucormycosis[J]. Microorganisms, 2025, 13(1): 55.
[8]	Groll AH, Townsend R, Desai A, et al. Drug-drug interactions between triazole antifungal agents used to treat invasive aspergillosis and immunosuppressants metabolized by cytochrome P450 3A4[J]. Transpl Infect Dis, 2017, 19(5): e12751.
[9]	Van Matre ET, Evans SL, Mueller SW, et al. Comparative evaluation of isavuconazonium sulfate, voriconazole, and posaconazole for the management of invasive fungal infections in an academic medical center[J]. Ann Clin Microbiol Antimicrob, 2019, 18(1): 13.
[10]	Arrieta AC, Neely M, Day JC, et al. Safety, tolerability, and population pharmacokinetics of intravenous and oral isavuconazonium sulfate in pediatric patients[J]. Antimicrob Agents Chemother, 2021, 65(8): e0029021.
[11]	Segers H, Deville JG, Muller WJ, et al. Safety, outcomes, and pharmacokinetics of isavuconazole as a treatment for invasive fungal diseases in pediatric patients: a non-comparative phase 2 trial[J]. Antimicrob Agents Chemother, 2024, 68(12): e0048424.
[12]	Ashkenazi-Hoffnung L, Bilavsky E, Levy I, et al. Isavuconazole as successful salvage therapy for mucormycosis in pediatric patients[J]. Pediatr Infect Dis J, 2020, 39(8): 718-724.
[13]	Gunathilaka SS, Keragala RK, Gunathilaka KM, et al. Use of isavuconazole in mucormycosis: a systematic review[J]. BMC Infect Dis, 2025, 25(1): 25.
[14]	崔颖, 钟旭丽, 刘碧晴, 等. 艾沙康唑治疗儿童造血干细胞移植围手术期肺毛霉病一例[J]. 临床药物治疗杂志, 2024, 22(2): 87-89.
	Cui Y, Zhong XL, Liu BQ, et al. Isavuconazole in the treatment of pulmonary mucormycosis in children undergoing hematopoietic stem cell transplantation: a case report[J]. Linchuang Yaowu Zhiliao Zazhi, 2024, 22(2): 87-89.
[15]	U.S.Food and Drug Administration. CRESEMBA label[EB/OL]. [2025-03-24]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/207500s016,207501s016lbl.pdf.
[16]	European Medicines Agency. CRESEMBA label[EB/OL].[2025-07-24]. https://www.ema.europa.eu/en/documents/product-information/cresemba-epar-product-information_en.pdf.
[17]	Andes D, Kovanda L, Desai A, et al. Isavuconazole concentration in real-world practice: consistency with results from clinical trials[J]. Antimicrob Agents Chemother, 2018, 62(7): e00585.
[18]	Fernández Ledesma B, Mendoza-Palomar N, Melendo Pérez S, et al. Isavuconazole use and TDM in real-world pediatric practice[J]. Antimicrob Agents Chemother, 2023, 67(12): e0082923.
[19]	Jendoubi A, Pressiat C, De Roux Q, et al. The impact of extracorporeal membrane oxygenation on antifungal pharmacokinetics: a systematic review[J]. Int J Antimicrob Agents, 2024, 63(2): 107078.
[20]	Biagi M, Butler D, Tan X, et al. Pharmacokinetics and dialytic clearance of isavuconazole during in vitro and in vivo continuous renal replacement therapy[J]. Antimicrob Agents Chemother, 2019, 63(12): e01085.
[21]	Perez L, Corne P, Pasquier G, et al. Population pharmacokinetics of isavuconazole in critical care patients with COVID-19-associated pulmonary aspergillosis and monte carlo simulations of high off-label doses[J]. J Fungi (Basel), 2023, 9(2): 211.

剂型	年龄	体重	负荷剂量	维持剂量
注射剂（以硫酸艾沙康唑鎓计）	1~<3岁	<18 kg	每次15 mg/kg，q8h，共6次	每次15 mg/kg，qd
	3~<18岁	<37 kg	每次10 mg/kg，q8h，共6次	每次10 mg/kg，qd
	3~<18岁	≥37kg	每次372 mg，q8h，共6次	每次372 mg，qd
胶囊（以硫酸艾沙康唑鎓计）	6~<18岁	16~<18 kg	每次149 mg，q8h，共6次	每次149 mg，qd
		18~<25 kg	每次233.5 mg，q8h，共6次	每次233.5 mg，qd
		25~<32 kg	每次298 mg，q8h，共6次	每次298 mg，qd
		≥32 kg	每次372 mg，q8h，共6次	每次372 mg，qd

剂型	年龄	体重	负荷剂量	维持剂量
注射剂（以艾沙康唑计）	1~<18岁	<37 kg	每次5.4 mg/kg，q8h，共6次	每次5.4 mg/kg，qd
注射剂（以艾沙康唑计）	1~<18岁	≥37 kg	每次200 mg，q8h，共6次	每次200 mg，qd
胶囊（以艾沙康唑计）	6~<18岁	16~<18 kg	每次80 mg，q8h，共6次	每次80 mg，qd
		18~<25 kg	每次120 mg，q8h，共6次	每次120 mg，qd
		25~<32 kg	每次160 mg，q8h，共6次	每次160 mg，qd
		32~<37 kg	每次180 mg，q8h，共6次	每次180 mg，qd
		≥37 kg	每次200 mg，q8h，共6次	每次200 mg，qd

艾沙康唑在儿童毛霉病治疗中的研究进展与临床思考

Research progress and clinical implications of isavuconazole in the treatment of pediatric mucormycosis

RichHTML

PDF (PC)

赞

可视化

摘要/Abstract

引用本文

使用本文

图/表 2

参考文献 21

相关文章 15

Metrics

本文评价

推荐阅读 0

[1]	胡燕, 杨凡, 梁爱民, 毛萌. 生长减缓儿童的识别与管理：第十三届国际营养与生长会议要点解读[J]. 临床儿科杂志, 2026, 44(6): 485-488.
[2]	刘子尧, 王聪颖, 王宏茂, 张明明, 许瑛杰, 赖建铭, 牛文全, 李晓惠. 伴关节症状川崎病与川崎病样症状起病全身型幼年特发性关节炎的早期鉴别：一项单中心回顾性研究[J]. 临床儿科杂志, 2026, 44(6): 489-498.
[3]	李健, 李涛, 何璐璐, 吴磊, 胡天骄, 黄怡璇, 林新蓉, 沈启阳, 潘思蕊, 谢男, 周建峰, 周春雷, 周莉. 儿童恶性横纹肌样瘤50例回顾性分析：临床特征、治疗反应及预后影响因素[J]. 临床儿科杂志, 2026, 44(6): 499-507.
[4]	李艳华, 张欢欢, 杨静薇, 廖雪莲, 邵静波, 焦瑒瑒, 张婷, 黄灿, 蒋莎义. 儿童头颈部横纹肌肉瘤生存预后及相关危险因素分析[J]. 临床儿科杂志, 2026, 44(6): 518-523.
[5]	石永媛, 杨丽娟, 雷文婷, 熊玉蓉, 潘书静, 李跃林, 张佳丽, 田茂强. 儿童自身免疫性脑炎合并运动障碍的临床特征及预后分析：一项单中心回顾性研究[J]. 临床儿科杂志, 2026, 44(6): 532-539.
[6]	顾信佳, 郑智慧, 梅伶俐, 郑金鑫, 刘太祥, 诸纪华. 1990—2023年中国儿童和青少年泌尿系统疾病负担研究[J]. 临床儿科杂志, 2026, 44(6): 546-555.
[7]	陈旭梅, 艾比白·艾尔肯, 岳雪艳, 茹凉, 张莉. 哮喘患儿家长心理弹性与应对方式的潜在剖面分析及影响因素研究[J]. 临床儿科杂志, 2026, 44(6): 556-563.
[8]	罗自豪, 李少军, 任佩珍, 王艳红, 耿刚. 儿童肺炎并发塑型性支气管炎临床特征分析及风险预测模型建立与验证[J]. 临床儿科杂志, 2026, 44(6): 564-572.
[9]	储卫红, 徐莉燕, 彭韶, 赖建铭. 以下肢动脉血栓为首发表现的儿童系统性红斑狼疮合并抗磷脂综合征2例报告[J]. 临床儿科杂志, 2026, 44(6): 579-583.
[10]	陈刘王, 刘盼, 席荣娟, 张先霞, 张毅, 韦性娇, 苏敏, 杨永红, 付扬喜. 甲基丙二酸血症合并同型半胱氨酸血症致儿童脊髓亚急性联合变性1例报告[J]. 临床儿科杂志, 2026, 44(6): 584-588.
[11]	中国妇幼保健协会儿童变态反应专业委员会中华医学会儿科学分会皮肤性病学组《临床儿科杂志》编辑委员会. 儿童特应性皮炎非药物干预管理专家共识[J]. 临床儿科杂志, 2026, 44(5): 381-393.
[12]	赵欣荣, 徐子刚. CARD14变异相关皮肤病的分子机制与诊治进展[J]. 临床儿科杂志, 2026, 44(5): 399-404.
[13]	郝延召, 李弯月, 李建国, 窦进法, 禹卉千, 王建波. 度普利尤单抗治疗儿童中重度特应性皮炎短期疗效与复发风险: 一项单中心回顾性研究[J]. 临床儿科杂志, 2026, 44(5): 412-417.
[14]	董瑛, 曹婷婷, 吴健平, 张莉, 葛宏松. 儿童和青少年掌跖黑素细胞痣的皮肤镜下特征分析[J]. 临床儿科杂志, 2026, 44(5): 418-423.
[15]	黄书越, 程明, 王稀欧, 宋弋, 杜牧, 宋福英, 曹冰燕. 儿童果糖-1，6-二磷酸酶缺乏症4例临床特征与文献复习[J]. 临床儿科杂志, 2026, 44(5): 438-444.